White Papers
The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter. The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised by Eric Drexler in his “Engines of Creation: The Coming Era of Nanotechnology” in 1986. Over the next 20 years the convergence of experimental advances in manipulation of materials no bigger than the width of a DNA molecule facilitated the development of this field from the closed confines of leading research labs into the world of applications for the general public. At the beginning of this century President Clinton put a political seal of approval on the sector by announcing the U.S. National Nanotechnology Initiative (NNI).
It is hard to believe the technology is almost 40 years old as it is only in the last 5-10 years that Nanotechnology has found favour in commercially viable products. Among areas where it is having the most significant impact is medicine.
White Papers
It’s easy to find trading and M&A multiples for mid and top tier CROs as their financial data are plentiful, often in the public domain and are the subject of discussion both in print and at conferences globally. Although consolidation in this sector is often dramatic and draws the attention of the entire industry, we should not lose sight of what is happening lower down the food chain, as it is these companies that will form the next generation of mid-tier CROs feeding further consolidation. It is a less defined sector of the market where data are much less available, and value more variable.
White Papers
Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical companies looking to bring new solutions to market and the mid size and smaller biotechs developing new approaches and seeking commercial partners.
White Papers
This presentation (available download on the left-hand side of this page) provides an overview of the EM opportunity, including some analysis of the financial performance of selected EM pharmaceutical industries and respective benchmark valuation metrics.
There is a brief section on the China opportunity, as it is by far the largest high growth market, and also an overview of healthcare in Latin America, which is a particularly promising EM region.
Additionally, this presentation also sets out a framework that can help life science/healthcare companies determine an effective EM strategy that is aligned with its broader growth objectives. External development options (eg. M&A) are outlined, including some key transaction considerations of doing deals in EMs.
White Papers
Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical manufacturing companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity in the industry as drugmakers consolidate to reduce costs, diversify product portfolios and expand geographic footprints. This whitepaper provides an overview of the pharmaceutical manufacturing landscape with a special focus on generics and biopharmaceuticals. PharmaVentures will also share unique insight gained from the divestment of manufacturing operations for some of the world’s leading pharmaceutical companies.
White Papers
In deal-making, options have long been considered a useful vehicle to carry uncertainty through to a point of resolution, or at least to a position of more understandable risk. Many very early stage players prefer the use of options to allow partners an opportunity to uncover value rather than undersell or worse allow good potential to gather dust for lack of resource. Would-be licensees see options as a lower risk / lower cost way of securing assets, seeing the risk reward balance falling in favour of watchful waiting. The pharmaceutical pipeline is a risky environment. Failure rates remain high despite all the advances in drug design and ever growing safety data.
